How pancreatic tumors use the MYC protein to evade immune detection

An international research team has succeeded in deciphering a key mechanism that controls the growth of pancreatic cancers.

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
EurekAlert!

Cancer’s super-enhancers may set the map for DNA breaks and repair: A key clue to why tumors become aggressive and genetically unstable

New study shows that cancer damages its own DNA by pushing key genes to work too hard. Researchers found that the most ...
InvestorsHub on MSN

Boundless Bio secures FDA green light to launch cancer drug study

Boundless Bio (NASDAQ:BOLD) said it has received clearance from the Food and Drug Administration for its investigational new ...
Fierce Biotech

Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs

Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026Portfolio prioritization, including ...

A new strategy to beat lung cancer: Chemists develop first-in-class inhibitor targeting a key epigenetic regulator

A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...

Breakthrough in Epigenetic Drug Discovery Targets Tumor Growth in Lung Cancer

In a groundbreaking advancement for cancer treatment, a research team led by Professor Xiang David Li from the Department of Chemistry at The University of Hong Kong (HKU) has made significant strides ...